Condition: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Hodgkin Lymphoma · Sponsor: University of Wisconsin, Madison
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.
This description comes directly from the study's public registry record.
Jenny Weiland · 608-890-8070 · PedsHemOncResearch@g-groups.wisc.edu
Celeste Matsushima · 608-890-8069
Always discuss trial participation with your own doctor first.
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02508038